SS Innovations International (NASDAQ: SSII), a developer of innovative surgical robotic technologies, has expanded the clinical footprint of its SSi Mantra surgical robotic system with the launch of a robotic cardiac surgery program at HCG Hospital, Mithakhali, in Ahmedabad, India. According to a company announcement, the program began with a robotic left internal mammary artery (LIMA) take-down performed by Dr. Brajmohan Singh and proctored by Dr. Lalit Malik, using the SSi Mantra advanced robotic surgical system. The procedure was supported by the SS Innovations team.
"We congratulate Dr. Brajmohan Sinh, Dr. Lalit Malik, and the entire team at HCG Hospital for this achievement, and thank them for their trust and commitment in advancing robotic cardiac surgery in the region," the company wrote in a LinkedIn post. "At SS Innovations International, Inc. we remain committed to enabling hospitals and…"
The expansion into cardiac surgery at HCG Hospital reflects SS Innovations' growing global presence. The company reported 238 SSi Mantra systems installed as of September 8, up 42% from the end of 2025. The system is now installed across 12 countries, with recent expansion into Colombia, Sri Lanka and the Philippines. SS Innovations is pursuing U.S. FDA review and European Union CE marking as it seeks to expand SSi Mantra into additional international markets.
This news matters because it demonstrates the increasing adoption of robotic-assisted surgery in emerging markets, potentially improving patient outcomes and access to advanced minimally invasive procedures. The launch of a cardiac program in India, a country with a high burden of cardiovascular disease, could signal a shift toward more advanced surgical options in the region. For investors, the growing installation base and international regulatory efforts suggest a company scaling its commercial reach, though it remains subject to risks and uncertainties as outlined in its SEC filings.
For more details, see the full release on www.newmediawire.com. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
This article includes forward-looking statements that involve risks and uncertainties. Actual results may differ materially. Undue reliance should not be placed on these statements when making an investment decision.
